All News

RheumNow Podcast square

The Great Unknowns (8.5.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.

Read Article
ACR guidance

ACR Updated Guideline on Vaccinations for Rheumatic Patients

Jack Cush, MD

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

Read Article
RheumNow Podcast square

Early, Aggressive and Seropositive (7.22.2022)

Jack Cush, MD

Dr. Jack Cush covers the news and journal reports from the past week on RheumNow.com. This week we have Insights NAFLD, overdose deaths, septic arthritis, refractory stills, & when MTX doesn’t work.

Read Article
Achilles,ankle,heel

Treating Enthesitis in Psoriatic Arthritis Patients

Jack Cush, MD

A large prospective psoriatic arthritis (PsA) study examined the enthesitis outcomes when PsA patients received conventional (cDMARDs) or targeted disease-modifying antirheumatic drugs (tDMARDs) and showed an overall 86% response rates, regardless of the medication used.

Read Article
RheumNow Podcast square

Fever Pitch (7.15.2022)

Jack Cush, MD

Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week on RheumNow.com

Read Article
Achilles,ankle,heel

Steroid Injection for Chronic Achilles Tendinopathy

MedPage Today

Adding a corticosteroid shot to exercise therapy significantly improved symptoms of chronic Achilles tendinopathy, a 100-person randomized trial found.

Read Article
2021,year

ICYMI: 2021 Rheumatology Year in Review

Jack Cush, MD

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
PsA Females: more likely to have Peripheral arthritis, have more pain, fatigue, poor function, lower QOL and less likely to have xray damage (than men) Males: more axial dz & severe psoriasis PsA Women may need more psychosocial support & pain management https://t.co/ZYWYu1K3jW https://t.co/xZX913vGdX

Links:

Dr. John Cush RheumNow ( View Tweet)
New Updated GRAPPA Psoriatic Arthritis Recommendations The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains." https://t.co/PkDofio1eh https://t.co/kp6UEgwonV

Links:

Dr. John Cush RheumNow ( View Tweet)
The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/vTM4x53n7k https://t.co/aQcuMury2k

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved a topical PDE4 inhibitor Roflumilast (Zoryve) a 0.3% cream for use in Plaque Psoriasis (Age 12 and Older) https://t.co/qDuCgUwmZV https://t.co/c0a7723A1X https://t.co/v5T66iKnvc

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center, retrospective chart study shows that in 168 PsA patients, 26% were assessed within 6wks of referral. Median wait time = 78.5 d. The most common cause of delay was the lack of available spots in the PsA clinic. https://t.co/FDfFgxHhLD https://t.co/CYoT1PBp8l

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders. https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/QUTIbK3r89 https://t.co/FZcTLREida

Links:

Dr. John Cush RheumNow ( View Tweet)
NHANES Cross-sectional study of 5672 psoriasis US adults (20-59 yrs) shows more NAFLD in PSO patients (33% vs 27% nonPSO) with an increased risk (OR 1.67) - moreso in men (OR 2.16), age 20-39 yrs (OR 2.48) & those without diabetes (OR 1.70) https://t.co/VfaJbMKboP https://t.co/dJlcLexDtn

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Survey: What do you rely on MOST in diagnosing Still’s disease? Sxs? Labs? Both? Criteria? Fever? Vote here: https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi

Links:

Dr. John Cush RheumNow ( View Tweet)
10% of PsA is PsA Sine Psoriasis - how to differentiate from seroneg RA? PsA sine PsO pts have peripheral arthritis, no skin dz, but may have axial sxs, +Family Hx or nail psoriasis, dactylitis, enthesitis, DIP involvement. https://t.co/2RjGU6Fw2j https://t.co/r7Dsqtksh5

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Comanagement of Psoriasis and Psoriatic Arthritis https://t.co/oo2Vhiwubq https://t.co/iikYssIepQ

Links:

Dr. John Cush RheumNow ( View Tweet)
2021 GRAPPA Recommendations - Looking Back, Looking Forward https://t.co/JzRCnh43QJ https://t.co/164AdDZCWz

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo Efficacy as early as 2 weeks No MACE, uveitis, IBD, deaths @RheumNow #EULAR2022 ABST#LB0001 cc:@doctorRBC : https://t.co/wgeBsfdQcL
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×